P3‐425: Safety, tolerability and efficacy of lecozotan SR in patients with mild‐to‐moderate Alzheimer's disease used as monotherapy or adjunctively with a cholinesterase inhibitor

Booth, Kevin; Zhao, Yonggang; Hua, Yue; Wilks, Kerri; Solomon, Paul R.; Lucas, Prisca; Murray, Ermellina; Raje, Sangeeta; Black, Ronald S.

doi:10.1016/j.jalz.2012.05.2099

Alzheimer's & Dementia

2012

DOI: 10.1016/j.jalz.2012.05.2099

|View full text |Cite

P3‐425: Safety, tolerability and efficacy of lecozotan SR in patients with mild‐to‐moderate Alzheimer's disease used as monotherapy or adjunctively with a cholinesterase inhibitor

Kevin Booth

Yonggang Zhao

Yue Hua

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis

Ahuja,

Siddhpuria,

Karimi

et al. 2023

Age and Ageing

View full text Add to dashboard Cite

Background Cholinesterase inhibitors are commonly used to treat patients with neurocognitive disorders, who often have an elevated risk of falling. Effective use of these medications requires a thoughtful assessment of risks and benefits. Objective To provide an update on previous reviews and determine the association between cholinesterase inhibitors and falls, syncope, fracture and accidental injuries in patients with neurocognitive disorders. Methods Embase, MEDLINE, Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature and AgeLine were systematically searched through March 2023 to identify all randomised controlled trials of cholinesterase inhibitors (donepezil, galantamine, rivastigmine) in patients with cognitive impairment. Corresponding authors were contacted for additional data necessary for meta-analysis. Inclusion criteria consisted of adults ≥19 years, with a diagnosis of dementia, Parkinson’s disease, mild cognitive impairment or traumatic brain injury. Data were extracted in duplicate for the aforementioned primary outcomes and all outcomes were analysed using random-effects meta-analysis. Results Fifty three studies (30 donepezil, 14 galantamine, 9 rivastigmine) were included providing data on 25, 399 patients. Cholinesterase inhibitors, compared to placebo, were associated with reduced risk of falls (risk ratio [RR] 0.84 [95% confidence interval [CI] = 0.73–0.96, P = 0.009]) and increased risk of syncope (RR 1.50 [95% CI = 1.02–2.21, P = 0.04]). There was no association with accidental injuries or fractures. Conclusion In patients with neurocognitive disorders, cholinesterase inhibitors were associated with decreased risk of falls, increased risk of syncope and no association with accidental trauma or fractures. These findings will help clinicians better evaluate risks and benefits of cholinesterase inhibitors.

show abstract

Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis

Ahuja,

Siddhpuria,

Karimi

et al. 2023

Age and Ageing

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P3‐425: Safety, tolerability and efficacy of lecozotan SR in patients with mild‐to‐moderate Alzheimer's disease used as monotherapy or adjunctively with a cholinesterase inhibitor

Cited by 1 publication

References 0 publications

Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis

Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis

Contact Info

Product

Resources

About